Senores Pharma.
Drug Manufacturers - General · SENORES
Small CapHealthcareEarly Growth
Swapnil Shah
Managing Director · Pragmatic
Company DNA
Founder-Centric
About
Senores Pharma. is a Small Cap company in the Healthcare sector, listed on NSE as SENORES. With a market cap of ₹3K Cr and revenue of ₹383 Cr, it is currently in the Early Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Early-growth stage firm with strong promoter involvement; strategy and operational execution are heavily tied to the founding leadership. Its strategic mandate: As a niche pharmaceutical entrant, the company needs a visionary leader to drive R&D differentiation and capture market share in competitive therapeutic segments.
FAQ
What kind of company is Senores Pharma.?
Senores Pharma. is a Small Cap Healthcare company (SENORES) in the Early Growth phase with a market cap of ₹3K Cr. It is classified as Founder-Centric in culture.
What is Senores Pharma.'s culture and work environment like?
Senores Pharma. has a Founder-Centric culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Early-growth stage firm with strong promoter involvement; strategy and operational execution are heavily tied to the founding leadership.
Who leads Senores Pharma.?
Senores Pharma. is led by Swapnil Shah (Managing Director), a Pragmatic leader with 18 years of experience.
What are Senores Pharma.'s financials?
Senores Pharma. reported revenue of ₹383 Cr in FY25 with a 5-year revenue CAGR of 200.8%. Operating margin: 19%. Market cap: ₹3K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandValue-Champion
LifecycleEarly Growth
Early-growth stage firm with strong promoter involvement; strategy and operational execution are heavily tied to the founding leadership.
Mandate
As a niche pharmaceutical entrant, the company needs a visionary leader to drive R&D differentiation and capture market share in competitive therapeutic segments.
As a niche pharmaceutical entrant, the company needs a visionary leader to drive R&D differentiation and capture market share in competitive therapeutic segments.
Financials
Revenue FY25₹383 Cr
PAT FY25₹59 Cr
Rev CAGR 5Y200.8%
OPM19%
NPM15.3%
ROE7.4%
ROCE7.4%
P/E28.2
Fwd P/E23
P/B4.4
D/E28.9
Mkt Cap₹3K Cr
Promoter56.7%
Institutional7.7%
Similar Culture
Could You Lead Senores Pharma.?
Take the Genome Benchmark →